Biotech | October 26, 2021
Biological E to receive US $ 50 million to boost Covid-19 vaccine capacity
Support from DFC will help produce one billion vaccine doses by the end of 2022
Support from DFC will help produce one billion vaccine doses by the end of 2022
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Prostate cancer is the second-most common cancer in men and despite an increase in the number of available treatments for men with mCRPC, five-year survival remains low
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
Subscribe To Our Newsletter & Stay Updated
